New triple therapy targets hard-to-treat bile duct cancer
NCT ID NCT07159217
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 27 times
Summary
This study tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) in 65 adults with advanced HER2-positive bile duct cancer that cannot be removed by surgery. The goal is to see how well the treatment shrinks tumors and how safe it is. Participants will be followed until their cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.